Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Triulzi, Tiziana"'
Autor:
Ligorio F; Metabolic Reprogramming in Solid Tumors Unit, IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Di Cosimo S; Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Verderio P; Bioinformatics and Biostatistics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ciniselli CM; Bioinformatics and Biostatistics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pizzamiglio S; Bioinformatics and Biostatistics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Castagnoli L; Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Dugo M; Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy., Galbardi B; Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy., Salgado R; Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium.; Sir Peter MacCallum Cancer Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia., Loi S; Sir Peter MacCallum Cancer Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia., Michiels S; Department of Biostatistics and Epidemiology, Gustave Roussy, Université Paris-Saclay, Villejuif, France., Triulzi T; Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., El-Abed S; Breast International Group (BIG), Brussels, Belgium., Izquierdo M; Novartis Pharma AG, Basel, Switzerland., de Azambuja E; Department of Medical Oncology, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), Bruxelles, Belgium., Nuciforo P; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Huober J; Breast Center, Cantonal Hospital St. Gallen, St. Gallen, Switzerland., Moscetti L; Department of Oncology-Hematology, University Hospital of Modena, Modena, Italy.; Gruppo Oncologico Italiano per la Ricerca Clinica, Parma, Italy., Janni W; Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany., Coccia-Portugal MA; Clinical Trial Department, Eastleigh Breast Care Center, Pretoria, South Africa., Corsetto PA; Department of Pharmacology and Biomolecular Science, University of Milan, Milan, Italy., Belfiore A; Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Lorenzini D; Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Daidone MG; Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Vingiani A; Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Oncology and Hemato-Oncology Department, University of Milan, Milan, Italy., Gianni L; Fondazione Michelangelo, Milan, Italy., Pupa SM; Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bianchini G; Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy.; Breast Cancer Unit - Department of Medical Oncology, Università Vita-Salute San Raffaele, Milan, Italy., Pruneri G; Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Oncology and Hemato-Oncology Department, University of Milan, Milan, Italy., Vernieri C; Metabolic Reprogramming in Solid Tumors Unit, IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Journal of the National Cancer Institute [J Natl Cancer Inst] 2022 Dec 08; Vol. 114 (12), pp. 1720-1727.
Autor:
Triulzi T; Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bianchini G; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy., Di Cosimo S; DRAST, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pienkowski T; Oncology and Breast Diseases Department, Postgraduate Medical Education Center, Warsaw, Poland., Im YH; Department of Medicine, Samsung Medical Center, Seoul, Republic of Korea., Bianchi GV; Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Galbardi B; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy., Dugo M; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy., De Cecco L; DRAST, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tseng LM; Taipei-Veterans General Hospital, National Yang-Ming University, Taiwan., Liu MC; Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan., Bermejo B; Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain., Semiglazov V; NN Petrov Research Institute of Oncology, St Petersburg, Russia., Viale G; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy., de la Haba-Rodriguez J; Hospital Reina Sofia, Córdoba, Spain., Oh DY; Division of Medical Oncology, Seoul National University Hospital Cancer Research Institute, Seoul National University College of Medicine, Republic of Korea., Poirier B; Centre des Maladies du sein, Hôpital du Saint-Sacrement, CHU de Québec, Canada., Valagussa P; Fondazione Michelangelo, Milan, Italy., Gianni L; Fondazione Michelangelo, Milan, Italy.; Fondazione Gianni Bonadonna, Milan, Italy., Tagliabue E; Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Molecular oncology [Mol Oncol] 2022 Jun; Vol. 16 (12), pp. 2355-2366. Date of Electronic Publication: 2021 Dec 17.
Autor:
Pizzamiglio S; Unit of Bioinformatics and Biostatistics, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ciniselli CM; Unit of Bioinformatics and Biostatistics, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Triulzi T; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Gargiuli C; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., De Cecco L; Platform of Integrated Biology, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., de Azambuja E; Institut Jules Bordet and l'Université Libre de Bruxelles (U.LB), Belgium., Fumagalli D; Breast International Group, Brussels, Belgium., Sotiriou C; Institut Jules Bordet and l'Université Libre de Bruxelles (U.LB), Belgium., Harbeck N; Brustzentrum der Universität München (LMU), München, Germany., Izquierdo M; Novartis Pharmaceutical, Basel, Switzerland., Nuciforo P; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Huober J; University of Ulm, Breast Center, Ulm, Germany., Cappelletti V; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Cinieri S; Antonio Perrino Hospital, Brindisi, Italy., Piccart M; Institut Jules Bordet and l'Université Libre de Bruxelles (U.LB), Belgium., Daidone MG; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pruneri G; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Colombo MP; Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Verderio P; Unit of Bioinformatics and Biostatistics, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Di Cosimo S; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. serena.dicosimo@istitutotumori.mi.it.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Dec 01; Vol. 27 (23), pp. 6307-6313. Date of Electronic Publication: 2021 Sep 21.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Viola Regondi, Stefania Arioli, Elda Tagliabue, Arianna Bonizzi, Francesca Bianchi, Beatrice Belmonte, Alessia Bertolotti, Claudio Tripodo, Andrea Balsari, Elena Fasano, Tiziana Triulzi, Loris De Cecco, Fabio Corsi, Martina Di Modica, Simone Guglielmetti, Giorgio Gargari, Laura Villani
Publikováno v:
Cancer research. 81(8)
Emerging evidence indicates that gut microbiota affect the response to anticancer therapies by modulating the host immune system. In this study, we investigated the impact of gut microbiota on immune-mediated trastuzumab antitumor efficacy in preclin
Autor:
Silvana Canevari, Andrea Balsari, Sylvie Ménard, Serena Di Cosimo, Marta Giussani, Aleix Prat, Marialuisa L. Carcangiu, Manuela Campiglio, Daniele Generali, Biagio Paolini, Elda Tagliabue, Loris De Cecco, Alberto Bottini, Tiziana Triulzi, Marco Sandri
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Oncotarget
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Oncotarget
While results thus far demonstrate the clinical benefit of trastuzumab, some patients do not respond to this therapy. To identify a molecular predictor of trastuzumab benefit, we conducted whole-transcriptome analysis of primary HER2+ breast carcinom